Alere Inc. (ALR)
Q2 2012 Earnings Call
August 8, 2012 8:30 AM ET
Doug Guarino – Director, Corporate Relation
Ron Zwanziger – Chairman and CEO
Dave Teitel – CFO
Dan Leonard – Leerink Swann
Jon Groberg – Macquarie Capital
John Putnam – Capstone Investments
Zarak Khurshid – Wedbush Securities
Isaac Ro – Goldman Sachs
Nicholas Jansen – Raymond James & Associates
Greg Simpson – Wunderlich Securities
Peter Lawson – Mizuho Securities
Good morning and welcome to the Alere Inc. Conference Call to discuss Second Quarter 2012 Results Conference Call. All participants will be in a listen-only mode. (Operator Instructions) Please note this event is being recorded.
And I would now like to turn the conference over to Doug Guarino, Director of Corporate Relations. Please go ahead.
Thank you, Emily, and good morning and welcome to the Alere conference call to discuss our results for the quarter ended June 30, 2012. We are joined today by Ron Zwanziger, Chairman and CEO, and Dave Teitel, CFO.
Before we get to that discussion though, I would first like to draw your attention to the fact that certain matters discussed in this conference call will constitute forward-looking statements within the meaning of the U.S. Securities Laws. These statements reflect our current views with respect to future events or financial performance and are based on management’s current assumptions and information currently available.
Actual results and the timing of certain events could differ materially from those projected or contemplated by the forward-looking statements due to numerous factors, including without limitation, our ability to successfully acquire and integrate our acquisitions and to recognize the expected benefits of restructuring and new business activities; our exposure to changes in interest rates and foreign currency exchange rates; our ability to successfully develop and commercialize products and services; the market acceptance of our products and services; continued acceptance of health management services by payers, providers and patients.